Over the past five years, oncology drug development has increased dramatically as a proverbial arms-race accelerated into the immune-oncology space. Some of the biggest names in Pharma began development internally, and scoured the globe for in-licensing and acquisition candidates to stake their claim to the next-generation of cancer standard of care.
With Oncology drug development making up over 30% of all industry-sponsored trials, growing at a 7.8% annually since 2005, it is prudent to step back and review just how successful this increased development has been. Some of the key names in Pharma – Roche/Genentech, Bristol-Myers, Merck, AbbVie and more, have all had widely varying success in the field of oncology.
The companies for which we provided detailed analysis include:
- Roche Holding AG
- Eli Lilly & Company
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Amgen, Inc.
- Celgene Corporation
- AbbVie, Inc.
- Merck & Co., Inc.
In this analysis, we break down key metrics of oncology success rates by disease group (Hematologic vs. Solids), by drug class (New Molecular Entity vs. Biologic) and on a company-by-company basis…
- See which top-pharma has the highest Phase II oncology candidate success rate. Find out not only their historical success rates, but review a deep-dive into what compounds and programs are driving those results for the top performing companies.
- Understand what candidates make or break a pipeline, and who ‘fails fast’, potentially saving millions on late-stage clinical development costs.
- Compare success rates by New Molecular Entity and Biologic.
- Discover the impact that the acquisitions of Medivation and Pharmacyclics had on the success rates of Pfizer and AbbVie respectively.
- Learn just how important Biomarker selection is in clinical success rates.
Table of Contents
• Pharmapremia Background + Success Rate Methodology
• Oncology Success Rates presented as a Complete Disease Area and Split Between Solid Tumor and Hematologic Malignancy Subsets
• Company-Specific Oncology Success Rates
• Company-Specific Solid Tumor Success Rates
– Deep-dive analysis into the success and failures of the top four companies
• Company-Specific Hematologic Malignancy Success Rate
– Deep-dive analysis into the successes and failures of the three key companies
• Assessment of the Impact that the Medivation Acquisition has had on Pfizer’s Clinical Success Rates
– This analysis in comparison to the Impact that a Medivation Acquisition would have had on Sanofi’s Clinical Success Rates
• Assessment of the Impact that the Pharmacylic Acquisition had on Abbvie’s Clinical Success Rates
• Oncology Success rates: Comparing NME development with that of Biologics across the Industry
• Oncology Success Rates: Comparing New Molecular Entity development with that of Biologics By Company
• Oncology Success Rate Changes over Time – Comparison of 2006-10 vs. 2011-15 Cohorts
– Data Details
– Abbreviations Used
Number of pages: 30